Procter & Gamble presented following test report after study
Intrinsa patch was produced in September 2004 which was tested on some surgically menopausal women for trial of product. Studies show that surgically menopause women have low sex desire due to less amount of testosterone in body. After the removal of ovaries the testosterone is not produced in body so female sexual dysfunction problem arises.
• Study of 562 patients: Intrinsa patch increased the frequency of satisfying sexual intercourse with 74%. The trial also showed 56% increased sexual desire in women. The patients who used Intrinsa reported an average of 2.13 sexual intercourses in 4 weeks compared to .98 sexual activities in women who used placebo.
• Study of 533 women: 49% women experienced increased sexual desire and 51% women experienced increased in the frequency of satisfying sexual intercourses. An average of 1.53 sexual episodes in four weeks for Intrinsa users compared to .73 for those on placebo.
Intrinsa patch was produced in September 2004 which was tested on some surgically menopausal women for trial of product. Studies show that surgically menopause women have low sex desire due to less amount of testosterone in body. After the removal of ovaries the testosterone is not produced in body so female sexual dysfunction problem arises.
• Study of 562 patients: Intrinsa patch increased the frequency of satisfying sexual intercourse with 74%. The trial also showed 56% increased sexual desire in women. The patients who used Intrinsa reported an average of 2.13 sexual intercourses in 4 weeks compared to .98 sexual activities in women who used placebo.
• Study of 533 women: 49% women experienced increased sexual desire and 51% women experienced increased in the frequency of satisfying sexual intercourses. An average of 1.53 sexual episodes in four weeks for Intrinsa users compared to .73 for those on placebo.
No comments:
Post a Comment